Integrated Filing (Financial) for the Quarter ended December 31, 2025.
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novartis India reported Q3 FY26 revenue from operations of ₹859.0 million, down about 7.6% from ₹930.0 million in the same quarter last year. Profit after tax for the quarter fell sharply to ₹160.9 million from ₹254.5 million a year ago, a decline of roughly 37%, hurt by higher current tax expense (which included a ₹55.6 million prior-year tax adjustment) and a one-time ₹16.8 million employee benefit provision linked to the new Labour Codes notified in November 2025. For the nine-month period, revenue declined 3.2% to ₹2,637.8 million while PAT eased 5.1% to ₹679.3 million. The company continues to carry no debt or outstanding defaults, and the statutory auditor (BSR & Co. LLP) issued a clean limited review report with no qualifications.
The year-on-year drop in both revenue and quarterly profit, combined with exceptional tax and labour-code-related costs, signals near-term pressure on earnings, though the debt-free balance sheet and single-segment pharma focus keep the overall profile stable for shareholders.